Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Related Citations for PubMed (Select 24922179)

1.

Drug development for pediatric neurogenic bladder dysfunction: dosing, endpoints, and study design.

Momper JD, Karesh A, Green DJ, Hirsch M, Khurana M, Lee J, Kim MJ, Mulugeta Y, Sachs HC, Yao L, Burckart GJ.

J Clin Pharmacol. 2014 Nov;54(11):1239-46. doi: 10.1002/jcph.345. Epub 2014 Jun 24.

PMID:
24922179
2.

Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007.

Momper JD, Mulugeta Y, Green DJ, Karesh A, Krudys KM, Sachs HC, Yao LP, Burckart GJ.

JAMA Pediatr. 2013 Oct;167(10):926-32. doi: 10.1001/jamapediatrics.2013.465.

PMID:
23921678
3.

Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop.

Jarow JP, Lerner SP, Kluetz PG, Liu K, Sridhara R, Bajorin D, Chang S, Dinney CP, Groshen S, Morton RA, O'Donnell M, Quale DZ, Schoenberg M, Seigne J, Vikram B.

Urology. 2014 Feb;83(2):262-4. doi: 10.1016/j.urology.2013.10.030. Epub 2013 Dec 12.

PMID:
24332121
4.

Pediatric antihypertensive trial failures: analysis of end points and dose range.

Benjamin DK Jr, Smith PB, Jadhav P, Gobburu JV, Murphy MD, Hasselblad V, Baker-Smith C, Califf RM, Li JS.

Hypertension. 2008 Apr;51(4):834-40. doi: 10.1161/HYPERTENSIONAHA.107.108886. Epub 2008 Mar 10.

5.

Pediatric drug development programs for type 2 diabetes: A review.

Christensen ML, Franklin BE, Momper JD, Reed MD.

J Clin Pharmacol. 2015 Mar 17. doi: 10.1002/jcph.497. [Epub ahead of print]

PMID:
25781151
6.

The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years.

Edginton AN, Shah B, Sevestre M, Momper JD.

Clin Pharmacokinet. 2013 Aug;52(8):693-703. doi: 10.1007/s40262-013-0065-6.

PMID:
23588537
7.

Pediatric drug labeling: improving the safety and efficacy of pediatric therapies.

Roberts R, Rodriguez W, Murphy D, Crescenzi T.

JAMA. 2003 Aug 20;290(7):905-11.

PMID:
12928467
8.

Leveraging prior quantitative knowledge in guiding pediatric drug development: a case study.

Jadhav PR, Zhang J, Gobburu JV.

Pharm Stat. 2009 Jul-Sep;8(3):216-24. doi: 10.1002/pst.394.

PMID:
19610013
9.

Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development.

Rivera DR, Hartzema AG.

Ann Pharmacother. 2014 Mar;48(3):369-79. doi: 10.1177/1060028013514031. Epub 2013 Dec 5. Review.

PMID:
24311725
10.

Anti-hypertensive drugs in children and adolescents.

Chu PY, Campbell MJ, Miller SG, Hill KD.

World J Cardiol. 2014 May 26;6(5):234-44. doi: 10.4330/wjc.v6.i5.234. Review.

11.

Which anticholinergic drug for overactive bladder symptoms in adults.

Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD005429. doi: 10.1002/14651858.CD005429.pub2. Review.

PMID:
22258963
12.
13.

Outcome measurement in female sexual dysfunction clinical trials: review and recommendations.

Althof SE, Rosen RC, DeRogatis L, Corty E, Quirk F, Symonds T.

J Sex Marital Ther. 2005 Mar-Apr;31(2):153-66. Review.

PMID:
15859374
14.

Extrapolation of adult data and other data in pediatric drug-development programs.

Dunne J, Rodriguez WJ, Murphy MD, Beasley BN, Burckart GJ, Filie JD, Lewis LL, Sachs HC, Sheridan PH, Starke P, Yao LP.

Pediatrics. 2011 Nov;128(5):e1242-9. doi: 10.1542/peds.2010-3487. Epub 2011 Oct 24.

15.

Steps toward harmonization for clinical development of medicines in pediatric ulcerative colitis-a global scientific discussion, part 2: data extrapolation, trial design, and pharmacokinetics.

Sun H, Vesely R, Nelson RM, Taminiau J, Szitanyi P, Isaac M, Klein A, Uzu S, Griebel D, Mulberg AE; International Inflammatory Bowel Disease Working Group.

J Pediatr Gastroenterol Nutr. 2014 Jun;58(6):684-8. doi: 10.1097/MPG.0000000000000322.

PMID:
24866782
16.

Impact of pediatric exclusivity on drug labeling and demonstrations of efficacy.

Wharton GT, Murphy MD, Avant D, Goldsmith JV, Chai G, Rodriguez WJ, Eisenstein EL.

Pediatrics. 2014 Aug;134(2):e512-8. doi: 10.1542/peds.2013-2987. Epub 2014 Jul 14.

PMID:
25022732
17.

Migraine therapeutics in adolescents: a systematic analysis and historic perspectives of triptan trials in adolescents.

Sun H, Bastings E, Temeck J, Smith PB, Men A, Tandon V, Murphy D, Rodriguez W.

JAMA Pediatr. 2013 Mar 1;167(3):243-9. doi: 10.1001/jamapediatrics.2013.872. Review.

PMID:
23359002
18.

Cardiovascular support in preterm infants.

Evans JR, Lou Short B, Van Meurs K, Cheryl Sachs H.

Clin Ther. 2006 Sep;28(9):1366-84. Review.

PMID:
17062310
19.

Improving pediatric dosing through pediatric initiatives: what we have learned.

Rodriguez W, Selen A, Avant D, Chaurasia C, Crescenzi T, Gieser G, Di Giacinto J, Huang SM, Lee P, Mathis L, Murphy D, Murphy S, Roberts R, Sachs HC, Suarez S, Tandon V, Uppoor RS.

Pediatrics. 2008 Mar;121(3):530-9. doi: 10.1542/peds.2007-1529.

20.

Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction.

Utomo E, Groen J, Blok BF.

Cochrane Database Syst Rev. 2014 May 24;5:CD004927. doi: 10.1002/14651858.CD004927.pub4. Review.

PMID:
24859260
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk